News & Updates

A combination regimen comprising the novel agent GST-HG171 (also known as atilotrelvir) and ritonavir improves clinical symptom recovery and viral clearance in low-risk vaccinated adults with mild-to-moderate COVID-19, findings from a pivotal phase II/III study have shown.

Hematochezia and abdominal pain are strong indicators of colorectal cancer (CRC), with the likelihood of CRC increasing by up to six- and 54-fold in the presence of such symptoms, according to a meta-analysis.

Increased body weight variability (BWV) contributes to adverse liver outcomes in people with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), a study has found. However, physical activity may attenuate such risk.

First-line treatment with tislelizumab plus chemotherapy for advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma yields better overall survival and an acceptable safety profile compared with chemotherapy plus placebo in patients with a programmed death-ligand 1 (PD-L1) tumour area positivity (TAP) score of ≥5 percent, a study has shown.

Women on testosterone therapy (TTh) show a lower risk of major adverse cardiac events (MACE) than matched controls, while postmenopausal women have a comparable MACE risk and a similar or significantly reduced risk of breast cancer on age-based subanalysis, reports a study.